For research use only, not for therapeutic use.
Ampreloxetine (TD-9855) is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine has the potential for the research of neurogenic orthostatic hypotension[1][2].
Ampreloxetine (0.3, 1, 5, 10, 30, 60 mg/kg; p.o.; single dose) shows a plasma EC50s of 11.7ng/mL and 50.8ng/mL in rat, respectively[1].
| Catalog Number | I009729 |
| CAS Number | 1227056-84-9 |
| Synonyms | 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine |
| Molecular Formula | C18H18F3NO |
| Purity | ≥95% |
| InChI | InChI=1S/C18H18F3NO/c19-14-9-16(20)18(17(21)10-14)23-11-13-3-1-2-4-15(13)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8,11H2 |
| InChIKey | TZIALEBTHQWNAO-UHFFFAOYSA-N |
| SMILES | C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F |
| Reference | [1]. Smith JA, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2):pyu027. [2]. Kaufmann H, et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res. 2021 Dec;31(6):699-711. |
